Darah Protas

Darah focuses her practice on the representation of both underwriters and issuers on a variety of capital markets transactions. Darah also regularly counsels publicly traded companies on general corporate matters, including SEC reporting and corporate governance.

Prior to joining Cooley, Darah was a corporate associate in Morrison & Foerster LLP’s San Francisco office.

While in law school, Darah served as executive managing editor of the Hastings Law Journal and as a moot court teaching assistant. She was also awarded the American Bankruptcy Institute Medal of Excellence and both the CALI and Witkin Awards for Academic Excellence in Antitrust, Bankruptcy and Legal Ethics. 

Representative company-side and underwriter-side public offerings:

• Dyne Therapeutics – $268 million IPO
• Prelude Therapeutics – $158 million IPO
• Orphazyme – $84 million IPO
• Vital Farms – $235.4 million IPO
• Passage Bio – $216 million IPO
• Zoetis, Inc. – $1.25 billion investment grade unsecured senior notes
• Entasis Therapeutics Holdings – $75 million IPO
• Tenable Holdings – $250.7 million IPO
• Translate Bio – $121.6 million IPO; $90 million follow-on offering
• Apellis Pharmaceuticals – $150 million IPO; $140.3 million follow-on offering; $117.3 million follow-on offering 

Representative company-side and bank-side private placements:

• Etsy, Inc. – $650 million senior convertible notes offering
• Apellis Pharmaceuticals – $220 million convertible senior notes
• Arbor Realty Trust, Inc. – $230 million convertible senior notes
• Inovio Pharmaceuticals – $78.5 million senior convertible notes offering
• Meredith Corporation – $3.5 billion senior notes offering; $300 million senior secured notes
• Translate Bio Inc. – $47.5 million common stock offering